Downregulation of Dystrophin Expression Occurs across Diverse Tumors, Correlates with the Age of Onset, Staging and Reduced Survival of Patients.

Alnassar, Nancy; Borczyk, Malgorzata; Tsagkogeorga, Georgia; Korostynski, Michal; Han, Namshik; Górecki, Dariusz C

Alnassar, Nancy; Borczyk, Malgorzata; Tsagkogeorga, Georgia; Korostynski, Michal; Han, Namshik; Górecki, Dariusz C.

Afiliação

Alnassar N; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2DT, UK.
Borczyk M; Laboratory of Pharmacogenomics, Maj Institute of Pharmacology PAS, 31155 Krakow, Poland.
Tsagkogeorga G; Milner Therapeutics Institute, University of Cambridge, Cambridge CB4 0WS, UK.
Korostynski M; STORM Therapeutics Ltd., Babraham Research Campus, Cambridge CB22 3AT, UK.
Han N; Laboratory of Pharmacogenomics, Maj Institute of Pharmacology PAS, 31155 Krakow, Poland.
Górecki DC; Milner Therapeutics Institute, University of Cambridge, Cambridge CB4 0WS, UK.

Cancers (Basel) ; 15(5)2023 Feb 21.

Article em En | MEDLINE | ID: mdl-36900171

Palavras-chave

DMD; cancer; duchenne muscular dystrophy; dystrophin; malignancy; sarcoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google